porcin
reproduct
respiratori
syndrom
viru
prrsv
positivestrand
rna
viru
grow
macrophag
caus
acut
pneumonia
pig
prrsv
caus
devast
loss
porcin
industri
howev
due
high
antigen
variabl
poorli
understood
immunopathogenesi
current
effect
vaccin
treatment
control
prrsv
infect
common
occurr
prrsv
infect
bacteri
infect
well
inflammatorydriven
pathobiolog
rais
question
valu
antibiot
immunomodul
properti
treatment
diseas
caus
macrolid
antibiot
tulathromycin
tul
found
exhibit
potent
antiinflammatori
immunomodul
properti
cattl
pig
aim
studi
character
antivir
immunomodul
properti
tul
prrsvinfect
porcin
macrophag
find
indic
blood
monocytederiv
macrophag
readili
infect
prrsv
use
effect
cellular
model
studi
prrsv
pathogenesi
tul
chang
intracellular
extracellular
viral
titer
alter
viral
receptor
express
porcin
macrophag
contrast
tul
exhibit
potent
immunomodul
properti
therefor
occur
absenc
direct
antivir
effect
prrsv
tul
addit
effect
prrsv
induct
macrophag
apoptosi
inhibit
virusinduc
necrosi
tul
significantli
attenu
prrsvinduc
macrophag
proinflammatori
signal
mitochondri
ro
product
prevent
prrsv
inhibit
nonopson
opson
phagocyt
function
togeth
data
demonstr
tul
inhibit
prrsvinduc
inflammatori
respons
porcin
macrophag
protect
phagocyt
impair
caus
viru
research
live
pig
warrant
assess
potenti
clinic
benefit
antibiot
context
viral
induc
inflamm
tissu
injuri
treat
hbss
control
tulathromycin
mgml
tul
uninfect
infect
prrsv
moi
hour
viru
tul
viru
stain
cell
diff
quick
reveal
infect
prrsv
alter
macrophag
morpholog
give
fibroblastlik
appear
viru
tul
treatment
prevent
alter
tulviru
repres
microscop
imag
independ
experi
bar
b
quantit
illustr
observ
shown
calcul
percentag
macrophag
exhibit
morpholog
chang
least
macrophag
count
experiment
group
data
repres
mean
sem
n
per
group
p
vs
control
p
vs
tul
p
vs
viru
respons
estim
loss
exceed
us
millionyear
usa
alon
porcin
reproduct
respiratori
syndrom
prr
devast
diseas
swine
industri
first
identifi
europ
north
america
late
syndrom
current
preval
swineproduc
countri
caus
agent
porcin
reproduct
respiratori
syndrom
viru
prrsv
small
envelop
positivesens
singlestrand
rna
viru
member
arteriviru
genu
sequenc
comparison
viral
isol
demonstr
prrsv
exist
least
two
distinct
genotyp
european
genotyp
eu
type
type
commonli
refer
north
american
genotyp
na
type
type
ii
known
prrsv
narrow
cell
tropism
may
induc
persist
asymptomat
infect
natur
host
viru
target
alveolar
macrophag
abl
infect
cell
monocytemacrophag
lineag
intravascular
lymph
node
macrophag
cell
play
crucial
role
immun
surveil
pathogen
kill
adapt
immun
respons
stimul
prrsv
impair
macrophag
phagocyt
bactericid
function
induc
host
cell
death
often
result
inflammatori
respons
perhap
importantli
predispos
pig
secondari
infect
inde
opportunist
pathogen
whether
viralswin
influenza
viru
pseudorabi
virusor
bacterialstreptococcu
sui
bordetella
brochisepticapotenti
prrsvinduc
pneumonia
synergist
effect
promot
selfsustain
inflammatori
respons
increas
sever
durat
diseas
common
occurr
prrsv
infect
bacteri
infect
combin
lack
effici
vaccin
beg
question
valu
antibiot
treatment
prr
tradit
antibiot
efficaci
evalu
sole
base
antimicrobi
properti
howev
macrolid
found
modul
ro
proinflammatori
cytokin
alter
product
lipid
mediat
regul
inflamm
antibiot
accumul
within
leukocyt
concentr
may
reach
time
system
level
turn
allow
transport
directli
site
infect
confer
superior
pharmacodynam
littl
evid
support
direct
antivir
properti
macrolid
effect
leukocyt
support
hypothesi
macrolid
may
benefici
context
viral
infect
prrsv
attempt
uncov
new
mechan
wherebi
macrolid
may
protect
detriment
effect
prrsv
present
studi
investig
effect
tulathromycin
porcin
monocytederiv
macrophag
tulathromycin
triamilid
lacton
compris
polar
amin
group
use
treatment
prevent
swine
respiratori
diseas
associ
actinobacillu
pleuropneumonia
gramneg
bacteria
often
found
prrsvinfect
pig
pleuropneumonia
exert
cytotox
effect
macrophag
neutrophil
increas
product
proinflammatori
also
known
leukotrien
b
ultim
lead
sever
pulmonari
tissu
damag
death
recent
studi
demonstr
addit
antimicrobi
effect
tulathromycin
inhibit
ltb
product
stimul
neutrophil
macrophag
addit
tulathromycin
promot
apoptot
death
neutrophil
phagocyt
clearanc
macrophag
phenomenon
known
efferocytosisboth
crucial
process
resolut
inflamm
hypothes
tulathromycin
may
gener
immunomodulatori
benefit
prrsvinfect
monocytederiv
macrophag
find
indic
tulathromycin
absenc
direct
antivir
effect
abl
restor
phagocyt
function
attenu
proinflammatori
phenotyp
prrsvinfect
monocytederiv
porcin
macrophag
african
green
monkey
kidney
cell
line
highli
permiss
prrsv
use
viral
passag
plaqu
titrat
assay
valid
previous
cell
cultiv
dulbecco
modifi
eagl
medium
dmem
thermo
fisher
scientif
waltham
usa
supplement
fb
invitrogen
carlsbad
ca
usa
iuml
penicillinstreptomycin
thermo
fisher
scientif
waltham
usa
cell
maintain
passag
twice
weekli
isol
nvsl
genbank
access
use
experi
previous
describ
viral
titrat
perform
via
plaqu
assay
briefli
cell
seed
well
plate
costar
sigma
aldrich
saintloui
mo
usa
grown
confluenc
confluenc
cell
infect
prrsv
hour
serumfre
dmem
allow
attach
viral
particl
follow
attach
overlaid
solut
mem
dilut
agaros
infect
carri
plaqu
reveal
neutral
red
sigmaaldrich
saintloui
mo
usa
dr
r
yate
univers
calgari
gener
provid
cell
line
isol
nvsl
anim
experiment
practic
care
conduct
accord
standard
canadian
council
anim
care
guidelin
approv
univers
calgari
life
environment
scienc
anim
care
committe
blood
collect
healthi
larg
white
landrac
cross
week
old
kg
femal
castrat
male
piglet
anim
hous
veterinari
scienc
research
station
univers
calgari
humid
light
cycl
consist
hour
continu
light
exposur
follow
hour
dark
piglet
fed
twice
antibioticfre
feed
hog
grower
hipro
feed
okotok
ab
canada
water
provid
ad
libitum
week
anim
euthan
tissu
made
avail
secondari
teach
research
use
accord
standard
canadian
council
anim
care
pig
euthan
intracardiac
inject
sodium
pentobarbit
monocyt
obtain
differenti
macrophag
describ
previous
briefli
blood
pool
centrifug
minut
x
g
heraeu
megafug
thermo
fisher
scientif
waltham
usa
plasma
remov
buffi
coat
layer
collect
dilut
filtersteril
nacl
steril
polysucros
sodium
diatrizo
gradient
solut
histopaqu
sigmaaldrich
saintloui
mo
usa
ad
tube
centrifug
minut
x
g
pbmc
locat
opaqu
interphas
collect
wash
sterilefilt
hank
balanc
salt
solut
hbss
thermo
fisher
scientif
waltham
usa
centrifug
minut
x
g
contamin
erythrocyt
remov
three
hypoton
lysi
cycl
steril
icecold
doubledistil
water
second
follow
addit
hbss
restor
tonic
pbmc
resuspend
serumfre
iscov
modifi
dubelcco
medium
imdm
thermo
ficher
scientif
waltham
usa
supplement
iuml
penicillinstreptomycin
cell
count
use
hemocytomet
viabil
assess
trypan
blue
exclus
flow
laboratori
pbmc
puriti
determin
diffquick
stain
cytospin
slide
cytocentrifug
thermo
fisher
scientif
waltham
usa
cell
plate
tissuecultur
treat
well
plate
costar
sigma
aldrich
saintloui
mo
usa
labtek
chamber
slide
thermo
fisher
scientif
waltham
usa
concentr
cell
ml
two
hour
allow
attach
follow
adhes
nonadher
mononuclear
cell
wash
warm
hbss
subsequ
adher
monocyt
incub
day
co
imdm
supplement
heat
inactiv
hi
pig
serum
ge
healthcar
chicago
il
usa
iuml
penicillinstreptomycin
supernat
allow
differenti
monocytederiv
macrophag
mdm
medium
commonli
use
potenti
monocyt
differenti
homogen
popul
matur
macrophag
cultur
media
chang
everi
day
flow
cytometri
use
quantifi
number
cell
express
known
cluster
differenti
monocyt
macrophag
isol
cell
express
fig
day
describ
previous
macrophag
differenti
monitor
microscop
morpholog
chang
use
diffquick
esteras
stain
well
known
featur
allow
distinguish
monocyt
matur
macrophag
day
cell
prepar
differenti
macrophag
data
shown
seven
daysold
differenti
macrophag
incub
tulathromycin
draxxin
zoeti
parsippanytroy
hill
nj
usa
dilut
imdm
hipig
serum
concentr
mgml
mgml
vehicl
control
imdm
pig
serum
establish
recent
concentr
time
point
drug
exhibit
immunomodul
properti
bovin
macrophag
without
induc
apoptosi
antibiot
like
tulathromycin
accumul
within
leukocyt
concentr
may
reach
time
system
level
turn
allow
transport
directli
site
infect
henc
confer
superior
pharmacodynam
phenomen
critic
mode
action
tulathromycin
drug
concentr
use
present
experi
consist
knowledg
previou
studi
show
tulathromycin
immunomodul
effect
bovin
porcin
neutrophil
macrophag
recent
studi
reproduc
immunomodul
effect
seen
vitro
drug
concentr
use
live
infect
cattl
pig
given
tulathromycin
recommend
therapeut
dosag
henc
concentr
use
reflect
physiolog
condit
drug
accumul
high
concentr
within
leukocyt
inde
comparison
intracellular
drug
concentr
treat
versu
untreat
anim
publish
previous
use
lc
ms
ms
anim
given
recommend
dose
mgkg
bodi
weight
studi
measur
rapid
prolong
distribut
drug
lung
homogen
pulmonari
epitheli
ling
fluid
pelf
well
pelf
cell
macrophag
major
constitu
pelf
cell
prepar
drug
level
measur
pelf
cell
reach
concentr
time
greater
plasma
believ
great
affin
cellular
uptak
may
relat
part
tribas
chemic
structur
drug
trap
ioniz
drug
within
acid
phagolysosom
macrophag
infect
prrsv
minut
tul
vehicl
treatment
infect
uninfect
control
incub
h
co
allow
viru
attach
entri
time
prrsv
dilut
serumfre
dmem
reach
multipl
infect
moi
rang
depend
experi
cultur
media
replac
prewarm
imdm
supplement
pig
serum
experiment
group
prrsv
infect
perform
anoth
hour
depend
experi
function
assay
contain
follow
experiment
group
untreat
uninfect
control
control
tulathromycintr
tul
untreat
prrsvinfect
viru
tulathromycintr
prrsvinfect
tulviru
lpsactiv
proapoptot
posit
control
staurosporin
st
pronecrot
posit
control
tritonx
tritx
appropri
avoid
cytokineinduc
polar
macrophag
macrophag
activ
experi
perform
monocyt
grown
supernat
free
effect
tulathromycin
prrsv
macrophag
differenti
activ
determin
via
microscop
observ
cytokin
quantif
mdm
treat
tulathromycin
mgml
hour
infect
prrsv
moi
co
supernant
collect
frozen
process
macrophag
stain
diffquick
electron
microscopi
scienc
hatfield
pa
usa
observ
nikon
eclips
microscop
assess
morpholog
chang
imag
taken
retiga
camera
q
imag
surrey
bc
canada
leica
dmr
fluoresc
microscop
leica
wetzlar
germani
analyz
use
imagej
softwar
individu
macrophag
morpholog
assess
classifi
rest
fibroblastlik
morpholog
least
macrophag
per
group
independ
experi
assess
supernat
process
measur
concentr
use
porcin
quantikin
enzymelink
immunosorb
assay
elisa
r
system
minneapoli
mn
usa
quantikin
elisa
r
system
minneapoli
mn
usa
respect
sampl
process
per
manufactur
instruct
ro
product
mdm
follow
tulathromycin
treatment
andor
prrsv
infect
monitor
oxiselect
intracellular
ro
assay
kit
cell
biolab
san
diego
ca
usa
experi
assess
ro
product
rest
cell
well
group
cell
induc
lipopolysaccharid
lp
determin
effect
variou
stimuli
basal
condit
cell
well
activ
mdm
infect
oi
uninfect
uninfect
control
treatment
perform
macrophag
stimul
lipopolysaccharid
lp
e
coli
sigmaaldrich
saintloui
mo
usa
mdm
expos
diacet
dcfhda
cellperm
fluorogen
probe
oxid
highli
fluoresc
dcf
ro
fluoresc
intens
proport
ro
level
within
cytosol
measur
use
spectramax
micropl
reader
molecular
devic
san
jose
ca
usa
read
nm
excit
nm
emiss
phagocyt
capac
mdm
assess
use
nonopson
zymosan
particl
opson
latex
bead
nonopson
phagocytosi
monitor
use
fluoresc
label
saccharomyc
cerevisia
zymosan
particl
texa
red
sigmaaldrich
saintloui
mo
usa
mdm
seed
labtek
chamber
slide
coverslip
cellsml
infect
hour
moi
infect
uninfect
control
follow
infect
experiment
group
incub
zymosan
particl
dilut
control
media
final
ratio
zymosan
cell
hour
exposur
extracellular
zymosan
particl
wash
away
warm
pb
cell
fix
icecold
aceton
solut
actin
stain
alexa
fluor
phalloidin
antibodi
thermo
fisher
scientif
waltham
usa
nucleu
reveal
dapi
thermo
fisher
scientif
waltham
usa
enumer
intracellular
zymosan
perform
use
leica
dmr
fluoresc
microscop
fcmediat
phagocyt
index
measur
use
carboxylatemodifi
diamet
latex
silica
bead
kisker
biotech
steinfurt
germani
coval
coat
bsa
human
igg
sigmaaldrich
saintloui
mo
usa
bead
subsequ
incub
macrophag
minut
bead
cell
ratio
follow
phagocytosi
extracellular
bead
wash
away
warm
pb
cell
stain
diffquick
electron
microscopi
scienc
hatfield
pa
usa
microscop
observ
macrophag
contain
one
zymosan
particl
latex
bead
consid
posit
cell
phagocyt
index
calcul
ratio
posit
macrophag
versu
total
macrophag
minimum
cell
per
experiment
group
count
randomli
select
field
pictur
taken
use
leica
dmr
fluoresc
microscop
retiga
q
imag
surrey
bc
canada
analyz
use
imagej
softwar
order
prevent
count
bia
slide
label
cover
tape
prior
microscop
observ
proapoptot
effect
tulathromycin
prrsv
assess
use
cell
death
detect
elisa
kit
roch
accord
manufactur
instruct
previous
describ
absorb
measur
use
spectramax
micropl
reader
molecular
devic
san
jose
ca
usa
set
mdm
incub
tulathromycin
mgml
minut
infect
prrsv
moi
co
similar
experiment
treatment
conduct
cell
stimul
lp
e
coli
sigmaaldrich
saintloui
mo
usa
assess
apoptosi
activ
macrophag
experi
cell
incub
imdm
contain
hipig
serum
staurosporin
use
neg
posit
control
respect
annexin
v
stain
roch
perform
experiment
group
assess
apoptot
cell
death
stain
perform
per
manufactur
instruct
fluoresc
observ
use
leica
dmr
fluoresc
microscop
equip
hcx
pl
fluotar
object
apertur
imag
taken
hour
post
infect
p
retiga
q
imag
surrey
bc
canada
importantli
experi
measur
cytokin
ro
follow
measur
apoptosi
allow
adjust
concentr
tulathromycin
viru
level
apoptosi
detect
cell
henc
cell
death
would
factor
cellular
cytokin
ro
respons
necrosi
assess
determin
lactat
dehydrogenas
ldh
level
use
cytotox
detect
kit
roch
mdm
treat
vehicl
medium
alon
control
tulathromycin
minut
cell
infect
prrsv
moi
supplement
control
medium
triton
x
media
use
posit
control
supernat
collect
process
follow
manufactur
instruct
spectramax
micropl
reader
molecular
devic
san
jose
ca
usa
use
measur
ldh
concentr
sampl
nm
necrosi
express
absorb
ratio
experiment
cell
lysat
versu
absorb
control
arbitrarili
set
experiment
group
assess
duplic
assess
potenti
antivir
effect
tulathromycin
extracellular
intracellular
viral
particl
count
monitor
plaqu
titrat
assay
extracellular
count
supernat
harvest
hour
pi
incub
confluent
cell
h
describ
intracellular
count
macrophag
wash
twice
warm
phosphat
buffer
salin
pb
sigmaaldrich
saintloui
mo
usa
lyse
doubl
distil
water
exposur
thorough
mix
cellular
debri
spun
x
g
minut
supernat
harvest
incub
confluent
cell
describ
previous
prrsv
stain
perform
character
potenti
antivir
effect
cell
seed
labtek
chamber
slide
grown
confluenc
infect
prrsv
moi
co
prrsv
foci
number
size
reveal
use
antibodi
rti
llc
brook
sd
usa
fluoresc
ratio
calcul
use
imagej
five
field
view
per
well
count
per
sampl
express
level
prrsv
receptor
mdm
presenc
absenc
tulathromycin
assess
immunofluoresc
seven
day
old
mdm
cultiv
without
condit
medium
treat
hbss
control
tulathromycin
mgml
hour
murin
fibroblast
cell
line
known
secret
macrophagecoloni
stimul
factor
mcsf
wide
use
induc
macrophag
differenti
monocyt
prevent
differenti
monocytederiv
dendrit
cell
prior
stain
cell
wash
time
icecold
pb
remov
media
fix
paraformaldehyd
pb
minut
fix
cell
wash
time
cold
pb
stain
hour
rphycoerythrin
rpe
conjug
antibodi
biorad
hercul
ca
usa
fluorescein
isothiocyan
fitc
conjug
antibodi
biorad
hercul
ca
usa
dilut
respect
follow
stain
cell
wash
time
cold
pb
observ
leica
dmr
fluoresc
microscopi
fluoresc
ratio
randomli
select
field
calcul
use
softwar
imagej
imag
taken
retiga
camera
prevent
bia
slide
label
cover
tape
prior
microscop
observ
statist
analys
made
use
prism
softwar
data
express
mean
standard
error
mean
sem
data
set
test
normal
data
parametr
distribut
compar
use
student
ttest
oneway
anova
tukey
multipl
comparis
anlaysi
appropri
nonparametr
data
compar
kruskalw
test
everi
assay
minimum
separ
independ
experi
conduct
experiment
group
assay
duplic
triplic
statist
signific
establish
p
order
determin
whether
blood
monocyt
mdm
suscept
prrsv
isol
blood
monocyt
healthi
pig
cultur
period
day
medium
supplement
pig
serum
mimic
biolog
condit
plate
adher
monocyt
exhibit
round
shape
morpholog
approxim
diamet
fig
day
cell
display
larger
macrophagelik
morpholog
characterisit
cytoplasm
vacuol
fig
monocyt
differenti
also
measur
use
nonspecif
esteras
nse
stain
day
cell
esteraseposit
cell
onedayold
monocyt
significantli
less
suscept
prrsv
compar
day
old
differenti
mdm
fig
prrsv
viral
particl
number
increas
log
increas
mdm
log
increas
blood
monocyt
hour
pi
cell
type
prrsv
infect
reach
plateau
pi
fig
optim
macrophag
differenti
protocol
mdm
also
cultur
medium
monocyt
cultiv
medium
show
morpholog
cultiv
medium
devoid
consist
previou
data
microscop
observ
nse
stain
show
day
cell
macrophag
viral
titer
monocyt
incub
significantli
higher
hour
pi
compar
viral
titer
monocyt
cultiv
without
supernat
fig
number
prrsv
infecti
particl
significantli
elev
mdm
cultiv
time
point
infect
except
hour
pi
time
point
versu
mdm
cultiv
medium
supplement
hipig
serum
alon
fig
mdm
prrsv
infect
peak
h
pi
declin
afterward
wherea
continu
increas
hour
monocyt
fig
base
observ
chose
use
mdm
function
experi
unless
state
otherwis
consid
supernat
may
contain
cytokin
mcsf
could
influenc
macrophag
polar
confound
studi
decid
grow
cell
medium
contain
pig
serum
assess
macrophag
proinflammatori
signal
moreov
limit
impact
tulathromycin
prrsvinduc
apoptosi
macrophag
number
function
treat
cell
tulathromycin
concentr
mgml
decreas
prrsv
moi
concentr
neither
viru
drug
significantli
induc
mdm
apoptosi
experiment
time
point
data
shown
cell
treat
concentr
function
analysi
perform
hour
incub
prrsv
infect
induc
sharp
fibroblastlik
morpholog
alter
pseudopod
project
mdm
fig
uninfect
cell
control
tul
less
cell
exhibit
chang
morpholog
nearli
cell
exhibit
phenotyp
upon
prrsv
infect
fig
tulathromycin
pretreat
significantli
inhibit
morpholog
chang
mdm
fig
sinc
macrophag
shape
function
correl
hypothes
prrsvinduc
morpholog
chang
associ
chang
macrophag
activ
infect
mdm
prrsv
caus
increas
secret
hour
fig
prrsvinduc
secret
significantli
inhibit
mdm
pretreat
tulathromycin
fig
posit
control
lp
also
significantli
increas
product
fig
measur
product
mitochondri
ro
hallmark
pathogen
oxid
damag
inflam
tissu
prrsv
infect
significantli
increas
intracellular
ro
fig
tulathromycin
treatment
abolish
prrsv
lpsinduc
intracellular
ro
product
howev
notrestor
ro
level
control
valu
cell
expos
lp
prrsv
fig
interestingli
intracellular
ro
level
significantli
lower
mdm
incub
lp
prrsv
compar
mdm
stimul
lp
fig
result
indic
tul
inhibit
macrophag
proinflammatori
signal
anoth
set
experi
assess
effect
drug
cytokin
potent
antiinflammatori
properti
rest
mdm
produc
approxim
pgml
throughout
cours
experi
fig
prrsv
infect
cell
secret
significantli
less
compar
control
cell
hour
pi
fig
level
significantli
chang
versu
control
uninfect
cell
treat
tulathromycin
alon
howev
immunomodul
properti
tulathromycin
prrsvinfect
porcin
monocytederiv
macrophag
prrsvinduc
inhibit
abolish
cell
pretreat
tulathromycin
hour
post
infect
fig
tulathromycin
mgml
well
prrsv
alon
moi
posit
control
staurosporin
induc
mdm
apoptosi
h
postinfect
fig
combin
pretreat
tulathromycin
prrsv
moi
hour
show
addit
effect
induc
mdm
apoptosi
versu
singl
treatment
fig
confirm
data
cell
stain
annexin
v
phospholipidbind
protein
high
affin
earli
apotpt
marker
phosphatidylserin
ps
hour
tulathromycin
alon
prrsv
alon
induc
signific
level
apoptosi
compar
control
increas
vs
control
fig
cell
expos
combin
tulathromycin
immunomodul
properti
tulathromycin
prrsvinfect
porcin
monocytederiv
macrophag
prrsv
level
apotosi
almost
doubl
measur
cell
expos
singl
treatment
fig
prrsv
infect
moi
significantli
increas
level
ldh
produc
necrosi
hour
pi
fig
treatment
tulathromycin
significantli
reduc
prrsv
cell
necrosi
hour
fig
effect
tulathromycin
could
longer
detect
hour
tulathromycin
alon
alter
level
necrosi
fig
tritonx
tritx
use
pronecrot
posit
control
induc
necrosi
mdm
fig
anoth
set
experi
assess
effect
prrsv
tulathromycin
nonopson
opson
phagocyt
function
mdm
prrsv
infect
significantli
immunomodul
properti
tulathromycin
prrsvinfect
porcin
monocytederiv
macrophag
inhibit
phagocyt
function
cell
fig
prrsvinduc
phagocyt
inhibit
inhibit
tulathromycin
fig
tulathromycin
treatment
alon
alter
mdm
phagocytosi
versu
control
fig
phagocytosi
macrophag
engulf
multipl
antigen
time
addit
experi
assess
mdm
engulf
less
particl
ie
basal
phagocyt
indic
versu
cell
ingest
particl
ie
elev
phagocyt
indic
prrsv
infect
significantli
reduc
number
cell
high
phagocyt
indec
effect
abolish
tulathromycin
fig
tulathromycin
inhibit
prrsvinduc
reduct
basal
high
phagocyt
indic
fig
tulathromycin
alon
chang
either
mdm
phagocyt
indic
versu
control
result
obtain
cell
infect
hour
fig
anoth
set
experi
assess
whether
effect
tulathromycin
describ
associ
direct
antivir
properti
antibiot
porcin
mdm
fig
cell
fig
upon
incub
prrsv
extracellular
intracellular
viral
particl
enumer
via
plaqu
assay
tulathromycin
chang
intracellular
extracellular
viral
titer
either
cell
model
fig
verifi
result
cell
stain
fitcconjug
antiprrsv
nucleocapsid
antibodi
antibodi
size
number
viral
foci
calcul
presenc
absenc
tulathromycin
fig
tulathromycin
pretreat
alter
viral
titer
compar
exposur
prrsv
alon
fig
examin
effect
tulathromycin
prrsv
infect
experi
measur
viral
receptor
express
mdm
date
two
major
prrsv
receptor
extens
studi
entir
clear
one
two
receptor
essenti
prrsv
infect
sinc
medium
increas
viral
titer
hypothes
might
due
increas
cell
permiss
result
increas
prrsv
receptor
express
test
hypothesi
cultiv
monocyt
medium
contain
pig
serum
alon
medium
day
treat
tulathromycin
mdm
differenti
medium
devoid
express
receptor
approxim
cell
express
cell
express
tulathromycin
treatment
significantli
chang
percentag
posit
cell
respect
posit
cell
fig
upper
panel
fig
mdm
incub
supplement
medium
suffici
significantli
increas
number
posit
cell
mdm
posit
versu
less
pig
serum
supplement
medium
alon
addit
follow
exposur
abl
detect
posit
cell
fig
lower
panel
fig
tulathromcyin
treatment
follow
signific
effect
viral
receptor
express
experi
fig
lower
panel
fig
prr
one
devast
diseas
porcin
industri
treatment
option
control
prr
outbreak
limit
efficaci
vaccin
thwart
antigen
variabl
prrsv
diseas
sever
close
relat
abil
viru
dysregul
macrophag
function
induc
inflamm
therefor
hypothes
target
either
compon
may
repres
critic
element
novel
therapeut
approach
antiinflammatori
immunomodulatori
properti
macrolid
well
establish
whether
effect
may
benefici
context
viral
diseas
prr
remain
obscur
present
studi
assess
antivir
immunomodul
properti
tulathromycin
tul
prrsvinfect
porcin
macrophag
find
indic
tul
inhibit
prrsvinduc
inflammatori
respons
porcin
monocytederiv
macrophag
protect
phagocyt
impair
caus
viru
absenc
direct
antivir
effect
two
common
cellular
model
pam
cell
signific
limit
isol
pam
requir
bronchoalveolar
lavag
function
cell
depend
age
environ
anim
moreov
shortli
initi
respiratori
infect
alveolar
macrophag
replac
monocytederiv
macrophag
therefor
repres
key
cell
popul
hostprrsv
immunomodul
properti
tulathromycin
prrsvinfect
porcin
monocytederiv
macrophag
interact
monkey
epitheli
cell
origin
pig
therefor
present
experi
develop
use
simpl
porcin
monocytederiv
macrophag
model
system
character
impact
tulathromycin
prrsv
infect
previou
vitro
studi
shown
viru
could
infect
blood
monocytederiv
macrophag
mdm
consist
previou
find
monocyt
less
suscept
prrsv
differenti
monocytederiv
macrophag
addit
supernat
macrophag
differenti
significantli
increas
suscept
viru
compar
macrophag
cultiv
medium
supplement
pig
serum
alon
well
establish
supernat
sourc
mcsf
use
induc
macrophag
differenti
immunostain
prrsv
receptor
show
addit
immunomodul
properti
tulathromycin
prrsvinfect
porcin
monocytederiv
macrophag
strongli
upregul
posit
cell
posit
cell
abolish
express
result
indic
supernat
modul
express
prrsv
receptor
alon
suffici
prrsv
infect
consist
recent
observ
show
enabl
nonpermiss
cell
becom
suscept
increas
correl
increas
suscept
prrsv
supernat
known
contain
mcsf
littl
known
cytokin
chemokin
present
supernat
consid
express
induc
respect
treatment
increas
prrsv
infect
decreas
role
cytokin
modul
macrophag
suscept
infect
requir
investig
present
find
demonstr
mdm
readili
infect
prrsv
henc
repres
use
cellular
model
studi
prrsv
pathogenesi
suggest
recent
hallmark
prrsv
pathogenesi
resid
abil
alter
macrophag
surviv
function
henc
predispos
host
secondari
infect
correl
macrophag
morpholog
function
henc
provid
easi
way
monitor
immunomodul
properti
tulathromycin
prrsvinfect
porcin
monocytederiv
macrophag
chang
macrophag
polar
studi
found
prrsv
infect
dramat
alter
monocytederiv
macrophag
morpholog
induc
elong
phenotyp
numer
cytoplasm
pseudopod
recent
find
indic
pseudopod
promot
intercellular
junction
allow
prrsv
evad
host
immun
direct
intercellular
spread
tulathromycin
pretreat
suffici
prevent
prrsvinduc
pseudopod
format
morpholog
alter
macrophag
whether
tul
may
prevent
intercellular
junction
thu
hinder
prrsv
immun
evas
requir
research
test
hypothesi
chang
macrophag
morpholog
associ
alter
function
measur
product
proand
antiinflammatori
cytokin
respect
well
product
mitochondri
ro
potent
neutrophil
chemoattract
secret
macrophag
cell
type
critic
mediat
neutrophil
infiltr
inflam
tissu
present
find
demonstr
prrsv
potent
induc
monocytederiv
macrophag
viral
induc
secret
inhibit
tul
studi
live
anim
warrant
assess
whether
observ
suggest
tul
might
attenu
prrsvinduc
inflamm
inhibit
mitochondri
ro
product
hallmark
cell
stress
inflamm
contribut
prrsvinduc
tissu
damag
report
show
mitochondri
ro
product
implic
prrsvinduc
apoptot
death
cell
demonstr
prrsv
inde
induc
ro
product
porcin
monocytederiv
macrophag
product
inhibit
cell
pretreat
antibiot
tulathromycin
also
abl
restor
ro
level
control
lpsstimul
cell
lp
prrsv
expos
lp
prrsv
interestingli
condit
mdm
show
decreas
ro
product
compar
cell
expos
lp
suggest
prrsv
may
inhibit
intracellular
ro
product
mdm
bacteri
infectionsanoth
set
studi
sought
determin
whether
tul
inhibit
viralinduc
proinflammatori
coincid
increas
antiinflammatori
signal
found
viru
alon
abl
inhibit
secret
tul
block
effect
data
contrast
other
scientif
literatur
inde
gener
accept
prrsv
induc
product
increas
infect
fact
activ
cell
permiss
prrsv
unstimul
macrophag
research
necessari
explain
mechan
wherebi
prrsv
regul
product
tulathromycin
alon
induc
secret
suggest
mitochondri
ro
inhibit
tul
depend
product
taken
togeth
present
find
strongli
support
hypothesi
tulathromycin
may
attenu
prrsvinduc
inflamm
inhibit
product
proinflammatori
prevent
suppress
antiinflammatori
consist
previou
studi
found
prrsv
tul
induc
macrophag
apoptosi
present
find
also
illustr
tul
prrsv
haver
addit
proapoptot
effect
morevo
data
indic
prrsv
lead
cell
necrosi
effect
inhibit
tul
necrosi
known
exacerb
local
inflamm
induc
releas
cytotox
molecul
lead
extens
tissu
damag
cell
apoptosi
contribut
resolut
inflamm
research
live
prrsvinfect
anim
help
determin
whether
tul
abl
promot
resolut
prrsvinduc
pulmonari
inflamm
least
part
via
mechan
well
shift
local
cytokin
releas
proinflammatori
antiinflammatori
mediat
well
establish
prrsv
infect
pig
often
infect
secondari
pathogen
present
mechan
result
increas
secondari
infect
prrsv
infect
remain
incomplet
understood
studi
shown
prrsv
directli
abl
impair
macrophag
phagocytosi
turn
may
repres
key
element
develop
secondari
infect
macrophag
phagocytosi
trigger
phagocyt
receptor
includ
opson
receptor
fcr
pattern
recognit
receptor
mannos
receptor
activ
use
nonopson
zymosan
particl
iggcoat
latex
bead
present
find
demonstr
prrsv
significantli
inhibit
phagocyt
pathway
result
consist
previou
report
show
decreas
phagocytosi
latex
bead
live
bacteria
streptococcu
sui
upon
prrsv
infect
recent
find
suggest
inhibit
phagocytosi
interact
sialoadhesin
also
refer
howev
model
system
cultiv
mdm
neg
suggest
either
mechan
inhibit
phagocytosi
strain
andor
genotyp
depend
prrsv
may
inhibit
phagocytosi
multipl
pathway
anoth
report
recent
demonstr
strain
use
may
impair
phagosom
matur
nadph
oxidasemedi
respiratori
burst
implic
antimicrobi
properti
macrophag
tul
block
prrsvinduc
inhibit
nonopson
iggmedi
macrophag
phagocytosi
observ
pave
way
toward
studi
vivo
assess
whether
antibiot
might
help
control
secondari
infect
prrsv
infect
mechan
addit
direct
antimicrobi
properti
mechan
wherebi
tul
protect
prrsvinduc
inhibit
phagocytosi
requir
elucid
macrolid
tilmicosin
tylvalosin
recent
demonstr
possess
direct
antivir
effect
prrsv
other
like
erythromycin
experi
describ
herein
tul
exhibit
direct
antivir
properti
significantli
alter
express
two
receptor
use
viru
entri
togeth
data
indic
porcin
mdm
tul
abl
block
prrsvinduc
pseudopod
format
necrosi
proinflammatori
mitochondri
ro
product
inhibit
macrophag
phagocytosi
addit
tul
also
synerg
prrsv
induc
proresolut
cell
apoptosi
product
antiinflammaotri
result
also
show
protect
modul
macrophag
structur
function
behavior
tul
occur
absenc
direct
antivir
effect
present
observ
pave
way
toward
studi
strain
determin
whether
effect
observ
studi
conserv
prrsv
genotyp
studi
vivo
help
determin
whether
effect
may
translat
clinic
benefit
